Get the Stockscreener App
6.18
9.19%
0.52
After Hours:
6.34
0.16
+2.59%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $6.18, with a volume of 5.72M.
It is up +9.19% in the last 24 hours and up +60.10% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$5.66
Open:
$5.64
24h Volume:
5.72M
Relative Volume:
1.28
Market Cap:
$644.84M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-3.7683
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
+46.10%
1M Performance:
+60.10%
6M Performance:
+51.47%
1Y Performance:
-11.71%
1-Day Range:
$5.60
$6.22
1-Week Range:
$4.19
$6.4399
52-Week Range:
$2.90
$7.73
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
6.18 | 590.58M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - The Manila Times
Altimmune raises $75 million to fund MASH therapy development - Investing.com
Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial - Stock Titan
Evercore ISI lowers Altimmune stock price target to $22 from $25 - Investing.com Canada
Revenue Check: Is Altimmune Inc a speculative investmentDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag For Obesity-MASH DrugAnd What's Next - Yahoo Finance
Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly - Yahoo Finance
Altimmune (NASDAQ:ALT) Trading 16.1% HigherShould You Buy? - MarketBeat
Altimmune Stock Surges After FDA Breakthrough for MASH Therapy - StocksToTrade
Stock Traders Purchase High Volume of Call Options on Altimmune (NASDAQ:ALT) - MarketBeat
Booz Allen Posts Upbeat Q3 Earnings, Joins Life360, Redwire And Other Big Stocks Moving Higher On Friday - Benzinga
ALT stock rallies 4% — what does retail think? - MSN
Altimmune (ALT) Receives FDA Breakthrough Therapy Designation, Shares Rise Nearly 4% - Intellectia AI
Decliners Report: Can Altimmune Inc stock outperform in a bear marketJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - baoquankhu1.vn
Rate Hike: Is Altimmune Inc stock a value trapJuly 2025 News Drivers & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Bitcoin Whales Accumulate While Retail Investors Withdraw - Intellectia AI
Altimmune receives FDA’s breakthrough therapy designation for its liver disease drug - MSN
Is Altimmune Inc a strong candidate for buy and holdPortfolio Update Report & Risk Managed Investment Signals - baoquankhu1.vn
Market Pulse: Can Altimmune Inc keep up with sector leadersOptions Play & Growth Focused Stock Reports - baoquankhu1.vn
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
RSI Check: Can Stran Company Inc Equity Warrant beat the S P 500Portfolio Risk Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Rally Mode: Is Altimmune Inc stock a good pick for beginners2025 Volume Leaders & Safe Entry Zone Tips - baoquankhu1.vn
Can Altimmune's Pemvidutide Follow In The Footsteps Of Rezdiffra And Wegovy In The MASH Landscape? - RTTNews
Dow Update: Will Altimmune Inc stock recover faster than peersJuly 2025 Chart Watch & Reliable Breakout Forecasts - moha.gov.vn
Will Altimmune Inc. stock benefit from upcoming earnings reports2025 Earnings Surprises & Advanced Technical Signal Analysis - Улправда
Enovix, Serve Robotics, EOG, Altimmune, Globalstar Shake Markets - TipRanks
Wayne Pisano Increases Stake in Altimmune Inc with Recent Share Purchase - GuruFocus
Wayne Pisano Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune (ALT) Is Up 13.0% After FDA Breakthrough Tag For Pemvidutide In MASHHas The Bull Case Changed? - Yahoo Finance
Can Altimmune Inc. stock sustain free cash flow growthJuly 2025 Volume & Momentum Based Trading Ideas - ulpravda.ru
Published on: 2026-01-09 03:53:26 - ulpravda.ru
Entry Recap: Will Altimmune Inc. stock split attract more investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Will Altimmune Inc. stock split attract more investorsPortfolio Return Summary & Fast Moving Market Watchlists - ulpravda.ru
Swing Trade: Why Altimmune Inc. stock remains on buy listsJuly 2025 Selloffs & Smart Allocation Stock Reports - ulpravda.ru
Altimmune (ALT) Is Up 16.1% After FDA Breakthrough Nod For AI-Enhanced MASH Drug Trial – Has The Bull Case Changed? - simplywall.st
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - The Globe and Mail
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune’s Surprising Stock Surge: What’s Behind It? - StocksToTrade
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Altimmune shares rally after FDA awards breakthrough status to pemvidutide - MSN
Why Did Mobileye Stock Surge 8% Pre-Market Today? - Stocktwits
Altimmune (ALT) Surges on FDA Breakthrough Therapy Designation f - GuruFocus
Altimmune Receives FDA Breakthrough Therapy Designation For Pemvidutide In Mash - TradingView — Track All Markets
Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ) - Seeking Alpha
FDA grants breakthrough therapy status to Altimmune’s MASH drug By Investing.com - Investing.com Australia
Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug - TradingView — Track All Markets
Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Quiver Quantitative
Altimmune stock soars after FDA grants Breakthrough Therapy status By Investing.com - Investing.com Canada
Altimmune stock soars after FDA grants Breakthrough Therapy status - Investing.com
FDA grants breakthrough therapy status to Altimmune’s MASH drug - Investing.com
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - The Manila Times
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):